Gene Expression Signatures and Predictive Modelling in Combination Immunotherapy

Immune checkpoint inhibitors (CPIs) are arguably the most transformative advance in cancer treatment in the last decade. Nevertheless, despite improved outcomes and future promise, a vast majority of cancer patients today fail to benefit from CPIs. Checkmate Pharmaceuticals is conducting a phase Ib multi-center, open label study with checkpoint inhibitors (pembrolizumab) and a CpG‐A Toll‐like receptor 9 (TLR9) agonist in anti-PD-1 nonresponders with advanced cutaneous melanoma. Genialis partnered with Checkmate Pharmaceuticals to analyze clinical trial sequencing data to help identify molecular signatures of response using our end-to-end NGS data management & analysis platform, Genialis Expressions.

Get the case study here: